作　　者： (赵东陆）; (马军）;

机构地区： 哈尔滨血液病肿瘤研究所，150010

出　　处： 《白血病．淋巴瘤》 2017年第8期449-451,共3页

摘　　要： 第14届国际淋巴瘤大会（ICML）于2017年6月14日至17日在瑞士卢加诺隆重召开.3500多名来自世界各地的淋巴瘤领域专家、学者参会.特别是由中国抗淋巴瘤联盟（UCLI）和ICML共同举办的UCLI-ICML联合论坛,极大地提高了中国在世界淋巴瘤领域的学术地位.笔者在联合论坛中分享了中国在T细胞淋巴瘤治疗方面的经验.文章就大会在T细胞淋巴瘤治疗方面的进展进行简要介绍. The 14th International Conference on Malignant Lymphoma （ICML） was held in Lugano, Switzerland from June 14, 2017 to June 17, 2017. More than 3500 lymphoma experts and scholars attended this unprecedented conference. In particular, the Joint Forum on Union for China Lymphoma Investigators （UCLI）-ICML jointly organised by UCLI and ICML had greatly improved Chinese academic status in the field of lymphoma worldwide. Chinese experience on the treatment of T-cell lymphoma was exchanged during the conference. This paper reviews the recent progress in treatment of T-cell lymphoma in the meeting.

关 键 词： 淋巴瘤 细胞 组蛋白去乙酰化酶抑制剂 国际淋巴瘤大会